Loading...
Loading...
Latest 10-Q filed 12/15/2025 · Compared against 9/11/2025
Chat is set up on each filing report page.
Ask about this filing, its industry, or sector trends.
AI responses are generated from filing and peer context and may contain errors.
Item 1A. Risk Factors.
For a discussion of risk factors, please refer We operate in a rapidly changing environment that involves a number of risks, which could materially affect our business, financial condition or future results, some of which are beyond our control. In addition to the other information set forth in this Quarterly Report on Form 10-Q, the risks and uncertainties that we believe are most important for you to Iconsider are discussed in Part I-Item 1A of under the heading Risk Factors in our 2025 Annual Report on Form 10-K. There have been for the year ended April 30, 2025 (the "Annual Report"). During the six months ended October 31, 2025, there were no material changes to the risk factors containthat were disclosed in our Annual Report except as noted in Item 1A below.
Risks Related to the Ownership of our 2025 Annual Report on Form 10-K. AddiSecurities
Future sales and issuances of our Common Stock or rights to purchase our Common Stock, including pursuant to our Equity Incentive Plan and other equity securities could result in dilutional risk of the percentage ownership of our stockholders and uncertainties not currently known to us or that could cause our stock price to fall.
We expect that significant additional capital may be needed in the future to continue our planned operations, including conducting clinical trials, commercialization efforts, expanded RD activities and costs associated with operating a public company. To raise capital, we may sell Common Stock or other equity securities in one or more transactions at prices and in a manner we currently deem to determine from time to time. If we sell Common Stock or other equity securities, investors may be immmaterial also ly diluted by subsequent sales. Such sales may also result in materially adversely affect o dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to the holders of our business, financial conditionCommon Stock. As of December 12, 2025, there were 3,178,507 shares of our Common Stock outstanding. In addition, as of December 12, 2025 there were 380,440 shares of Series C Preferred Stock outstanding that, as of such date, were convertible into 290,919 shares of Common Stock, 542,467 shares of Series D Preferred Stock outstanding that, as of such date, were convertible into 542,467 shares of Common Stock and options, restricted stock units, and/ warrants exercisable for operating results2,922,204 shares of our Common Stock, of which 775,000 are reserved for issuance under the Plan, as amended and are subject to shareholder approval.